Generation of CAR T cells for adoptive therapy in the context of glioblastoma standard of care.

Published online

Journal Article

Adoptive T cell immunotherapy offers a promising strategy for specifically targeting and eliminating malignant gliomas. T cells can be engineered ex vivo to express chimeric antigen receptors specific for glioma antigens (CAR T cells). The expansion and function of adoptively transferred CAR T cells can be potentiated by the lymphodepletive and tumoricidal effects of standard of care chemotherapy and radiotherapy. We describe a method for generating CAR T cells targeting EGFRvIII, a glioma-specific antigen, and evaluating their efficacy when combined with a murine model of glioblastoma standard of care. T cells are engineered by transduction with a retroviral vector containing the anti-EGFRvIII CAR gene. Tumor-bearing animals are subjected to host conditioning by a course of temozolomide and whole brain irradiation at dose regimens designed to model clinical standard of care. CAR T cells are then delivered intravenously to primed hosts. This method can be used to evaluate the antitumor efficacy of CAR T cells in the context of standard of care.

Full Text

Duke Authors

Cited Authors

  • Riccione, K; Suryadevara, CM; Snyder, D; Cui, X; Sampson, JH; Sanchez-Perez, L

Published Date

  • February 16, 2015

Published In

PubMed ID

  • 25741761

Pubmed Central ID

  • 25741761

Electronic International Standard Serial Number (EISSN)

  • 1940-087X

Digital Object Identifier (DOI)

  • 10.3791/52397

Language

  • eng

Conference Location

  • United States